TodosMedical.png
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
24 sept. 2019 09h14 HE | Todos Medical Ltd.
REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
13 sept. 2019 09h05 HE | Intrommune Therapeutics
New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing the patient-friendly oral mucosal immunotherapy (OMIT) toothpaste platform for...
Momotaro Gene Logo.png
Momotaro-Gene Announces First Patient Dosed in Phase 2 Clinical Trial of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma
11 sept. 2019 07h30 HE | Momotaro-Gene
OKAYAMA, Japan, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of...
jpg.jpg
Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit
10 sept. 2019 07h00 HE | Incysus Therapeutics, Inc.
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Intrommune Logo Only - 250k.jpg
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food Allergies
05 sept. 2019 15h20 HE | Intrommune Therapeutics
New York, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2
29 août 2019 13h53 HE | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
28 août 2019 16h05 HE | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Fior-Markets-Logo.jpg
Global Liver Cancer Treatment Market is Expected to Reach USD 2,186.63 Million by 2025 : Fior Markets
27 août 2019 05h57 HE | Fior Markets
New Jersey, NJ, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Rising incidence of liver cancer and growing research activities for developing novel treatments. The global liver cancer treatment market is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Formulation Patent Notice of Allowance
21 août 2019 14h41 HE | Intrommune Therapeutics
New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Logo.jpg
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
13 août 2019 08h00 HE | Celsion CORP
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with Significance in Patients with...